A biotech venture based in Turku, Finland, called Therapeutica Borealis just secured a patent from the United States Patent and Trademark Office (USPTO) for its COVID-19 therapy based on ivermectin and a few other notable therapies: hydroxychloroquine and aprotinin. Developed as a nasal spray, which can challenge the virus’ ability to enter the body and replicate, this particular investigational product can be mass-produced at low cost and distributed to parts around the world where vaccination may be less pervasive. Now the company seeks pharmaceutical company partners to scale up research and go-to-market.
Based in a Dynamic R&D-Active Urban Area
This new venture known as Therapeutica Borealis is affiliated with the University of Turku and is located in Turku, Finland, in the far southwest. This city of only about 200,000 represents the nation’s top life sciences cluster, which is actually the source of nearly 70% of Finish biopharma exports. The city has a concentration of over 1,000 researchers distributed over more than 100 research groups making up what’s known as “Health Turku.”
The Investigational Product
This particular investigational nasal therapeutic pr...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).